Sirexatamab Plus Bevacizumab/Chemo Improves Outcomes in DKK1-High mCRC

Sirexatamab (DKN-01) in combination with bevacizumab (Avastin) and standard-of-care (SOC) chemotherapy demonstrated a manageable safety profile and was well tolerated vs bevacizumab plus SOC chemotherapy in patients with metastatic colorectal…